Skip to main content

Varian and the changing nature of cancer care

Ted for website
MRI CT Scan

This article appears in our Q3 2019 Quarterly Report.1

Sadly, it is now a rare person who hasn’t felt the shock and sadness of a loved one fighting cancer. This single term for a family of diseases is now the second largest cause of death globally.  It accounts for about one sixth of all deaths.  And the incidence is rising.2  In 1990 around 0.70% of the world’s population were suffering from the disease.  That proportion was 0.87% in 2017.  By 2040 it is forecast to rise to nearer to 1.5%.3

Why?

There are two key reasons for this new epidemic.  Longer lives ironically increase the risks of cancer.  So do a variety of risk factors that modern life makes harder to avoid.

We are making progress

The good news is that treatments are improving.  Those treatments are in five categories.  Medical oncology and immuno-oncology use drugs.  Surgical oncology and Interventional oncology use physical interventions.  And radiation oncology uses radiation to destroy cancer cells.

Each of these disciplines is able to provide the best-fit solution for different situations.  And all of them have made huge advances in recent years.   Huge progress has also been made in the critical techniques that support treatment, such as screening, diagnosis, treatment planning, and symptom management.

The success has been impressive.  Here in the UK, the number of people surviving five years from diagnosis increased by 21% from 2010 to 2015.The key is combining all the ingredients of modern cancer care successfully.  Varian Medical Systems (“Varian”) has mirrored this journey from independent specialism to a holistic approach.

Radiation oncology

Varian started as a true originator of radiation oncology.  In 1960 it produced the “Clinac 6”, one of the first commercial linear accelerators (“linacs”) for cancer treatment.5  Linacs deliver a focused dose of X-rays to destroy cancer cells.  The linac is a flexible and versatile tool and its introduction was a huge leap forward.

Varian originally developed the linac because they had expertise in microwave tubes and nuclear test apparatus.  They had a technology and were looking for applications.   Over the years, its focus on the medical linac grew and grew.  But its heritage remained, a technology-led company, specialising in radiation oncology.

A business transformation

Then in the last decade, this focus began to shift.  In addition to perfecting the linac, Varian invested more in developing software.  This included treatment and cancer care solutions, taking the focus beyond just the machinery.

A symbolic change came at the start of 2017.  Varian span out its imaging business, separately listing it as Varex Imaging.   The whole of Varian’s portfolio is now focused on cancer treatments.  The focus is the disease, and how to treat it, rather than the technology, and what to do with it.

So Varian is now a leader in proton therapy, and more powerful and targeted new form of radiation therapy.  It has gathered a series of interventional oncology treatments.  These include, for example, microbeads that block the blood flow to a tumour.  Varian is still also developing its software portfolio at an impressive rate.

With all these changes, the company claims to now “touch” four million cancer patients each year.  This is an increase from two million only four years ago.6

This shift has also changed the business model.  There is more research.  R&D spending is up from around 6.5% of sales a decade ago to 8%.7  In the same time period, recurring services and software sales have risen to around 50%, from 30%.  And the reliance on the US has fallen to below 50%.  All attractive features to long term investors like WHEB.

We opened our position in Varian in September 2013.  We’ve been supportive investors through this transformation.  Our process is to focus on sustainability challenges, and to address them as directly as possible.  We like management teams that demonstrate clear strategic thinking and focus on impact.

Areas of high unmet need

There is still more than this to like about Varian.  Another important cancer statistic is that 70% of cancer deaths come from low- and middle- income countries.8 Varian launched its low-cost Halcyon linac, developed for those markets, in May 2017.  Of the 284 Halcyon machines sold since then, 75% are in places where there has not been radiation oncology before.9 It has also acquired an Indian business called Cancer Treatment Services International (CTSI).  CTSI is proving that affordable high-quality cancer care can be financially viable.  Varian wants to roll that model out. Varian’s impact on lives and livelihoods around the world is profound.  We’re proud to be apart of it.

1 https://www.whebgroup.com/impact-investment-funds/sustainability-fund-oeic/quarterly-reports-fp-wheb-sustainability-fund-oeic

2 https://ourworldindata.org/cancer

3 http://gco.iarc.fr/tomorrow/graphic-isotype?type=0&population=900&mode=population&sex=0&cancer=39&age_group=value&apc_male=0&apc_female=0

4 https://www.macmillan.org.uk/_images/cancer-statistics-factsheet_tcm9-260514.pdf

5 https://www.varian.com/about-varian

6 Varian management at American Society for Radiation Oncology Meeting, 16 Sept 2019, per transcript

7 Varian management at American Society for Radiation Oncology Meeting, 16 Sept 2019, per transcript and presentation

8 https://www.who.int/cancer/resources/keyfacts/en/

9 Varian 3Q19 report 24 July 2019

10 Varian management at American Society for Radiation Oncology Meeting, 16 Sept 2019, per transcript

11 Varian management at American Society for Radiation Oncology Meeting, 16 Sept 2019, per transcript and presentation

12 https://www.who.int/cancer/resources/keyfacts/en/ 

13 Varian 3Q19 report 24 July 2019

Important Notices:
Risks include: the price of shares (“Shares”) in FP WHEB Sustainability Fund, WHEB Sustainable Impact Fund or WHEB Environmental Impact Fund may increase or decrease and you may not get back the amount originally invested, for reasons including adverse market and foreign exchange rate movements. Past performance does not predict future returns. The Fund invests in equities and is exposed to price fluctuations in the equity markets, and focuses on investments in mid-sized companies in certain sectors so its performance may not correlate closely with the MSCI World Index (the benchmark). For full risks, please see fund prospectus on www.whebgroup.com

 

General: This information, its contents and any related communication (altogether, the “Information”) is issued by WHEB Asset Management LLP (“WHEB Asset Management”). It is intended for information purposes only and does not constitute or form part of any offer or invitation to buy or sell any security including any shares in the FP WHEB Sustainability Fund or WHEB Sustainable Impact Fund, including in the United States. It should not be relied upon to make an investment decision in relation to Shares in the FP WHEB Sustainability Fund or WHEB Sustainable Impact Fund or otherwise; any such investment decision should be made only on the basis of the Fund scheme documents and appropriate professional advice. This Information does not constitute advice of any kind, investment research or a research recommendation, is in summary form and is subject to change without notice. The performance shown does not take account of any commissions and costs charged when subscribing to and redeeming shares. WHEB Asset Management has exercised reasonable care in preparing this Information including using reliable sources, however, makes no representation or warranty relating to its accuracy, reliability or completeness or whether any future event may or may not occur. This Information is only made available to recipients who may lawfully receive it in accordance with applicable laws, regulations and rules and binding guidance of regulators. WHEB Asset Management LLP is registered in England and Wales with number OC 341489 and has its registered office at 7 Cavendish Square, London, W1G 0PE. WHEB Asset Management LLP is authorised and regulated by the Financial Conduct Authority with Firm Reference Number 496413.

 

FP WHEB Sustainability Fund

FundRock Partners Limited (formerly Fund Partners Limited) is the Authorised Corporate Director of the Fund and is authorised and regulated by the Financial Conduct Authority with Firm Reference Number 469278 and has its registered office at 6th Floor Bastion House, 140 London Wall, London, EC2Y 5DN. The state of the origin of the Fund is England and Wales. The Representative in Switzerland is ACOLIN Fund Services AG, Leutschenbachstrasse 50, CH-8050 Zurich, whilst the Paying Agent is NPB Neue Privat Bank AG, Limmatquai 1/am Bellevue, P.O. Box, 8024 Zurich . The relevant documents such as the prospectus, the key investor information document (KIIDs), the Articles of Association as well as the annual and semi-annual reports may be obtained free of charge from the Representative in Switzerland.

 

WHEB Sustainable Impact Fund

The Manager of the Fund is FundRock Management Company S.A., authorised and regulated by the Luxembourg regulator to act as UCITS management company and has its registered office at 33, rue de Gasperich, L-5826 Hesperange, Grand-Duchy of Luxembourg. The Representative in Switzerland is ACOLIN Fund Services AG, Leutschenbachstrasse 50, CH-8050 Zurich, whilst the Paying Agent is NPB Neue Privat Bank AG, Limmatquai 1/am Bellevue, P.O. Box, 8024 Zurich. The relevant documents such as the prospectus, the key investor information document (KIIDs), the Articles of Association as well as the annual and semi-annual reports may be obtained free of charge from the representative in Switzerland. The state of the origin of the Fund is Ireland. The Fund is registered for distribution to professional investors in Austria, France, Germany, Italy, Luxembourg, Norway, Singapore, Sweden and the United Kingdom, and is registered for offering to retail investors in Switzerland, Denmark and the Netherlands. The Fund is also available for professional investors in Belgium and Hong Kong. It is not available to investors domiciled in the United States.

 

WHEB Environmental Impact Fund

The Manager of the Fund is FundRock Management Company S.A., authorised and regulated by the Luxembourg regulator to act as UCITS management company and has its registered office at 33, rue de Gasperich, L-5826 Hesperange, Grand-Duchy of Luxembourg. The Fund is registered for distribution to professional investors in the United Kingdom. It is not available to investors domiciled in the United States.

 

The MSCI information may only be used for your internal use, may not be reproduced or re-dissseminated in any form and may not be used as a basis for or a component of any financial instruments or products or indices. None of the MSCI information is intended to constitute investment advice or a recommendation to make (or refrain from making) any kind of investment decision and may not be relied on as such. Historical data and analysis should not be taken as an indication or guarantee of any future performance analysis, forecast or prediction. The MSCI information is provided on an “as is” basis and the user of this information assumes the entire risk of any use made of this information. MSCI, each of its affiliates and each other person involved in or related to compiling, computing or creating any MSCI information (collectively, the “MSCI Parties”) expressly disclaims all warranties (including, without limitation, any warranties of originality, accuracy, completeness, timeliness, non-infringement, merchantability and fitness for a particular purpose) with respect to this information. Without limiting any of the foregoing, in no event shall any MSCI Party have any liability for any direct, indirect, special, incidental, punitive, consequential (including, without limitation, lost profits) or any other damages (www.msci.com).

Sign up to impact fund updates

Sign up below to receive email updates on our impact investment funds.
{{ errors[0] }}
{{ errors[0] }}
{{ errors[0] }}
{{ errors[0] }}
{{ errors[0] }}
{{ errors[0] }}
Authorised and regulated by the Financial Conduct Authority Copyright 2024© WHEB. All rights reserved Made by Thursday
How to invest